nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2014 | editorial

ASCO 2014: news, hopes, hypes?

verfasst von: Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Excerpt

This year’s American Society of Clinical Oncology (ASCO) saw some major improvements in the treatment of patients with solid tumors which, however, did not lead to a change in current clinical practice; at least not in the treatment of those solid tumors which will be reported within this summary. Surprisingly not all the therapeutic progress stems from targeted therapy but also from long-known substances like aromatase inhibitors. In total, more than 5000 abstracts have been presented at ASCO 2014. Within this review the most important abstracts covering head and neck tumors, breast cancer, melanoma, lung cancer, and colorectal cancer will be presented and put into context regarding actual clinical practice. …

Vorheriger Artikel International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform

Nächster Artikel Contribution of the vascular bone marrow niche to leukemia progression

Pagani O, Regan MM, Walley B, et al. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014;32:5s (suppl; abstr LBA1).CrossRef

Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol. 2014;32(Suppl. 18):LBA4.

Haddad R, OʼNeill AO, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013;14(3):257–64.PubMedCrossRef

Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216–25.PubMedCrossRef

Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43..PubMedCrossRef

Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol. 2014;32:5s (abstract 6004).CrossRef

Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol. 2014;32:5s (abstr 9011).CrossRef

Yang JC, Sequist LV, Schuler M, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFRmut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 and LUX-Lung 6) comparing afatinib with chemotherapy (CT). J Clin Oncol. 2014;32;5s (suppl; abstr 8004).CrossRef

Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (Pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8008).CrossRef

10.

Venook A, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32:5s (suppl; abstr LBA3).CrossRef

11.

Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Proc ESMO. 2013, Abstract LBA17.

Titel: ASCO 2014: news, hopes, hypes?
verfasst von: Wolfgang Eisterer
Publikationsdatum: 01.12.2014
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0189-x

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Melanoma 2014—an update

Gene signature profiling of gynaecological malignancies

Angiogenesis inhibition in renal cell cancer

Stem cell transplantation for acute myeloid leukaemia in adults

Angiogenesis

Latest developments in the treatment of metastatic colorectal cancer: update ASCO 2014